TELO — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• We had net losses of $1.7 million and $5.1 million for the three months ended June 30, 2026 and 2025, respectively. We had net losses of $2.7 million and $7.3 million for the six months ended June 30, 2026 and 2025, respectively.

• Research and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of contracted research and manufacturing, consulting arra…

• We incurred $1.3 million and $5.0 million in general and administrative expenses during the three months ended June 30, 2026 and 2025, respectively. The decrease in general and administrative expenses of $3.7 million during the three months ended June 30, 2026 relates primarily to decreases in stock…

• We incurred research and development expenses of $0.4 million and less than $0.1 million during the three months ended June 30, 2026 and 2025. The increase in R&D expenses during the three months ended June 30, 2026 primarily reflects higher pre-clinical research and R&D consultant costs associated …

• The following categorized various elements of R&D expense during the three months ended June 30, 2026 and 2025:

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• We had net losses of $0.9 million and $2.2 million for the three months ended March 31, 2026 and 2025, respectively.

• At the Effective Time, Telomir’s stockholders will continue to own and hold their existing shares of Common Stock. Following the Merger, Common Stock will continue to be listed on the Nasdaq under the symbol “TELO”.

• Research and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following:

• ● other expenses incurred to advance the Company’s research and development activities.

• We incurred general and administrative expenses of $0.6 million and $1.9 million during the three months ended March 31, 2026 and 2025, respectively. General and administrative expenses in the three months ended March 31, 2026 consisted primarily of stock-based compensation expense of approximately …

Text added vs the prior filing · source: 10-Q · 2026-08-13

• From time to time, we may become involved in legal proceedings, claims, investigations and other matters arising in the ordinary course of our business. Except as described below, we are not currently a party to any material pending legal proceeding.

• On June 5, 2026, a complaint was filed by the Estate of Christopher Columbus Chapman, Jr., a former Chief Executive Officer of the Company, in the circuit court of Miami-Dade County, Florida claiming that the Company failed to timely transfer restricted common stock of the Company. The Company subse…

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• From time to time, we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations, or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to…

• We anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial resources to defend against …